uniQure (NASDAQ: QURE) reported Q2 2026 financial results and confirmed that U.S. and U.K. regulatory filings for AMT-130, its investigational gene therapy for Huntington's disease, remain on track for Q3 2026. The company expects four-year Phase 1/2 topline data in September and reported encouraging early Phase I/IIa data for AMT-260. uniQure also said the FDA supports an accelerated approval pathway for AMT-130 and ended the quarter with $810.3 million in cash, providing a financial runway into 2030. Sector: Biotechnology / Gene Therapy Key Highlights 🧬 AMT-130 regulatory filings remain on track for Q3 2026 📊 Four-year Phase 1/2 topline data expected in September ✅ FDA supports an accelerated approval pathway for AMT-130 🔬 Reported encouraging early Phase I/IIa data for AMT-260 💰 Ended Q2 with $810.3 million in cash, funding operations into 2030 Why It Matters uniQure continues to make meaningful progress toward the potential commercialization of AMT-130, while its strong cash position and advancing pipeline strengthen its long-term outlook in gene therapy. https://www.thinksabio.com/reports/isr/QURE